News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Stephanie Yip

Advertisement

Articles by Stephanie Yip

opioids trials ADFs.png

Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and Cannabis

ByHeidi Chen,Laurie Withington,Stephanie Yip
November 10th 2018

Analysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.

Advertisement

Latest Updated Articles

  • opioids trials ADFs.png
    Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and Cannabis

    Published: November 10th 2018 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up

2

Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement

3

Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments

4

Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial

5

Novo Nordisk Stock Reacts to Recent Board Changes

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us